Avian Influenza (H9 Subtype) Vaccine, Inactivated (Strain HN106)

Name: Avian Influenza (H9 Subtype) Vaccine, Inactivated (Strain HN106)
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1940673812

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$3.99-9.99

1 Piece

Sample price:US$1.00/piece.Request sample

Product profile

Customization

Available

Varieties

Infectious Disease Prevention Medicine

Component

Chemical Synthetic Drugs

Type

The First Class

Pharmacodynamic Influential Factors

Animal Species

Storage Method

Prevent High or LowTemperature

Transport Package

Carton

Specification

(1)100 dose /bottle (2)250 dose /bottle (3)500 dos

Trademark

QIXIANG

Origin

Zhengzhou, Henan Province

HS Code

300230000

Production Capacity

30000bottles/Month

Key features

Effective H9 Vaccine: Inactivated vaccine targeting Avian Influenza H9 subtype strain HN106.

Long Immunization: Provides immunity for 5 months after proper administration.

Flexible Dosage: 0.3ml for chickens 1-5 weeks; 0.5ml for chickens over 5 weeks.

OEM/ODM Support: ODM and OEM services available with 20 R&D engineers.

Fast Delivery: Average lead time is one month for both peak and off-season.

Global Reach: Exports to North America, Europe, Asia, Africa, and Australia.

Manufacturer Direct: Direct from factory with 360 employees and 16,000 sqm plant.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤10.52h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.